Positive Phase III data on RedHill’s RHB-104 in Crohn’s disease

Israel-based specialty pharma company RedHill Biopharma (TASE: RDHL) saw its shares rocket nearly 46% to $0.56 pre-market as it revealed positive new trail results.

RedHill announced the new publication of ground-breaking positive data from its Phase III Crohn’s disease study with RHB-104, showing that RHB-104 plus standard of care (SoC), targeting Mycobacterium avium subspecies paratuberculosis (MAP), was 64% more effective than SoC alone in the study, supporting the hypothesis of a Mycobacterial basis to the disease.

* Newly published in the peer-reviewed journal Antibiotics, the 331-patient Phase III Crohn’s disease study data shows the primary endpoint of clinical remission at week 26 was achieved, with high statistical significance, in 36.7% (61/166) of orally administered RHB-104 plus standard of care (SoC) patients, compared to 22.4% (37/165) of placebo plus SoC patients (p=0.0048); Safety profile similar to placebo. Study conducted across more than 100 sites